U.S. markets closed

Otonomy, Inc. (OTIC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1600+0.0400 (+1.89%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.1200
Open2.1600
Bid2.1700 x 1000
Ask2.2300 x 2200
Day's Range2.1538 - 2.2700
52 Week Range2.1100 - 6.9830
Volume475,428
Avg. Volume1,125,024
Market Cap122.295M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
      Zacks

      Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?

      Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

    • Benzinga

      ROCE Insights For Otonomy

      During Q4, Otonomy (NASDAQ:OTIC) brought in sales totaling $53.00 thousand. However, earnings decreased 2.2%, resulting in a loss of $10.29 million. Otonomy collected $50.00 thousand in revenue during Q3, but reported earnings showed a $10.52 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Otonomy posted an ROCE of -0.16%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on OTIC Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders. In Otonomy's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions. Q4 Earnings Recap Otonomy reported Q4 earnings per share at $-0.2/share, which beat analyst predictions of $-0.22/share. See more from BenzingaClick here for options trades from Benzinga12 Health Care Stocks Moving In Monday's Pre-Market SessionEarnings Scheduled For February 11, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • MarketWatch

      Otonomy stock loses half its value after disappointing trial results of vertigo treatment

      Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary endpoint. "We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per protocol analysis," said Chief Executive David Weber. He said the company's focus turns to the "strong pipeline," highlighted by the "successful" clinical trial results of its tinnitus and hearing loss treatments, with clinical readouts anticipated in mid-2022. Weber said he expects the company's existing cash balance is enough to to achieve the clinical readouts. The stock has rallied 51.8% over the past 12 months through Friday, while the iShares Nasdaq Biotechnology ETF has advanced 35.1% and the S&P 500 has gained 17.1%.